TAIWAN

Seven Years of Uninterrupted Growth: Andes Technology Achieves Milestone Annual Revenue Exceeding NT$1 Billion

Retrieved on: 
Thursday, March 21, 2024

Andes has invested capital and R&D manpower to accelerate the launch of high-end products to ensure long-term competitiveness and maintain market leadership.

Key Points: 
  • Andes has invested capital and R&D manpower to accelerate the launch of high-end products to ensure long-term competitiveness and maintain market leadership.
  • In 2023, even when the whole industry was still under inventory pressure, Andes surpassed a significant total shipment milestone of 14 billion Andes-Embedded™ SoCs.
  • In 2023, the diverse product portfolio offered by Andes has resonated exceptionally well with the market and enabled its sustained growth.
  • More recently, Andes ventured into the application processor market with the launch of its cutting-edge out-of-order (OOO) processor AX65.

New Industry Report Asks Whether 2024 is Living Up to Expectations for Offshore Wind?

Retrieved on: 
Thursday, March 21, 2024

The Q1 report looks at whether 2024 is still expected to deliver on that promise.

Key Points: 
  • The Q1 report looks at whether 2024 is still expected to deliver on that promise.
  • In 2023 the global offshore wind sector fully commissioned 7 GW, and this has been followed by 592 MW in Q1 2024.
  • Additionally, the report noted that 2024 is poised to witness a surge in corporate power purchase agreements (PPAs).
  • TGS releases regular intelligence reports on a wide variety of offshore energy subjects, powered by 4C Offshore market intelligence.

Sportradar Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Wednesday, March 20, 2024

ST. GALLEN, Switzerland, March 20, 2024 (GLOBE NEWSWIRE) -- Sportradar Group AG (NASDAQ: SRAD) (“Sportradar” or the “Company”), a leading global sports technology Company focused on creating immersive experiences for sports fans and bettors, today announced financial results for its fourth quarter and year ended December 31, 2023.

Key Points: 
  • Segment revenue in the fourth quarter of 2023 increased by 25% to €132.0 million compared with the fourth quarter of 2022.
  • Segment revenue in the fourth quarter of 2023 increased by 28% to €52.7 million compared with the fourth quarter of 2022.
  • Personnel expenses in the fourth quarter of 2023 increased 10% to €88.8 million, compared with the fourth quarter of 2022.
  • Other Operating expenses in the fourth quarter of 2023 decreased 30% to €24.4 million compared with the fourth quarter of 2022, primarily driven by non-recurring litigation costs that occurred in the fourth quarter of 2022.

Taiwan hosts 11th Smart City Summit & Expo, showcasing global innovations

Retrieved on: 
Wednesday, March 20, 2024

This annual event, highlighting smart city applications in transportation and net-zero solutions, is a collaboration between the city of Kaohsiung, the Taiwan Smart City Solutions Alliance (TSSA) and the Taipei Computer Association.

Key Points: 
  • This annual event, highlighting smart city applications in transportation and net-zero solutions, is a collaboration between the city of Kaohsiung, the Taiwan Smart City Solutions Alliance (TSSA) and the Taipei Computer Association.
  • Also, Presidential Office Secretary-General Lin Chia-lung emphasized Taiwan's leading role in ICT and semiconductor AI, stressing that Taiwan can contribute and lead in the smart city and green city nexus.
  • "I believe that smart cities must be green cities, and to become green, they must be smart cities," he added.
  • Set to take place in Taipei and Kaohsiung, the SCSE will also feature a "Net Zero City Leaders Summit" and a City COP Forum, fostering substantive global city collaborations.

Sportradar Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Wednesday, March 20, 2024

ST. GALLEN, Switzerland, March 20, 2024 (GLOBE NEWSWIRE) -- Sportradar Group AG (NASDAQ: SRAD) (“Sportradar” or the “Company”), a leading global sports technology Company focused on creating immersive experiences for sports fans and bettors, today announced financial results for its fourth quarter and year ended December 31, 2023.

Key Points: 
  • Segment revenue in the fourth quarter of 2023 increased by 25% to €132.0 million compared with the fourth quarter of 2022.
  • Segment revenue in the fourth quarter of 2023 increased by 28% to €52.7 million compared with the fourth quarter of 2022.
  • Personnel expenses in the fourth quarter of 2023 increased 10% to €88.8 million, compared with the fourth quarter of 2022.
  • Other Operating expenses in the fourth quarter of 2023 decreased 30% to €24.4 million compared with the fourth quarter of 2022, primarily driven by non-recurring litigation costs that occurred in the fourth quarter of 2022.

ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine

Retrieved on: 
Tuesday, March 19, 2024

FREMONT, CA, March 19, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, proudly announced today that its CEO, Dr. Uttam Patil, was selected as one of the Top 10 CEOs in Taiwan 2024 by CEO Insights Asia Magazine .

Key Points: 
  • FREMONT, CA, March 19, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, proudly announced today that its CEO, Dr. Uttam Patil, was selected as one of the Top 10 CEOs in Taiwan 2024 by CEO Insights Asia Magazine .
  • Dr. Patil is confident in the Company's prospects, so he owns stock options without claiming a salary.
  • CEO Insights Asia writes that Dr. Patil, "a unique amalgamation of scholarly acumen and practical insight fuels a forward-thinking approach, steering companies toward sustained success and pioneering innovation ( CEO Insight Asia 19) ".
  • ABVC urges its shareholders to sign up on the Company's website for the latest news alerts; visit https://abvcpharma.com/?page_id=17707

23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago

Retrieved on: 
Tuesday, March 19, 2024

"23andMe's Historical Matches is a technical breakthrough in our ability to accurately detect genetic connections between customers and historical individuals."

Key Points: 
  • "23andMe's Historical Matches is a technical breakthrough in our ability to accurately detect genetic connections between customers and historical individuals."
  • The new Historical Matches feature leverages the same science applied in a more consumer-friendly and approachable way to making these connections.
  • To create this new feature and connect members to Historical Matches, 23andMe identifies segments of DNA that individuals share with the genetic sequences of historical individuals.
  • The feature relies on publicly available data, scientific publications, and the 23andMe relative matching technology to link to these historical individuals.

Semilux International Ltd. Launches Strategic R&D Collaboration Program on Solid-State Automotive LiDAR Module to Explore the Frontier in Autonomous Driving Technology

Retrieved on: 
Monday, March 18, 2024

Sponsored by the National Science and Technology Council in Taiwan, the Program is at the forefront of R&D and application of the Optical Phased Array (“OPA”), a key area of LiDAR technology which is expected to transform the autonomous driving industry.

Key Points: 
  • Sponsored by the National Science and Technology Council in Taiwan, the Program is at the forefront of R&D and application of the Optical Phased Array (“OPA”), a key area of LiDAR technology which is expected to transform the autonomous driving industry.
  • The Program is designed to overcome the weakness in the current OPA technology for solid-state automotive LiDAR module.
  • The Company plans to complete the Program by 2025 and divides it into three phases in the process as follows.
  • Experts from National Chung Hsing University, Turing Drive, and Industrial Technology Research Institute also participate in this program.

Ragnarok Origin, Grand Launch in China on March 26, 2024!

Retrieved on: 
Monday, March 18, 2024

Seoul, March 18, 2024 (GLOBE NEWSWIRE) -- GRAVITY Co., Ltd. (NasdaqGM: GRVY) (“Gravity” or “Company”), a developer and publisher of online and mobile games, today announced that Ragnarok Origin will launch in China on March 26, 2024.

Key Points: 
  • Seoul, March 18, 2024 (GLOBE NEWSWIRE) -- GRAVITY Co., Ltd. (NasdaqGM: GRVY) (“Gravity” or “Company”), a developer and publisher of online and mobile games, today announced that Ragnarok Origin will launch in China on March 26, 2024.
  • The game received a ISBN by Chinese government in August 2023.
  • Also, the game has been awarded Google Play’s Best Game 2023, Best Multiplayer, in Indonesia, Thailand and Singapore, and selected as Google Play Best 2020 Award in Korea.
  • Gravity Said, “We are very pleased to be able to finally introduce Ragnarok Origin to Chinese users who have waited for the launching since the release of the ISBN in August 2023.

OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform

Retrieved on: 
Monday, March 18, 2024

TAIPEI, Taiwan, March 18, 2024 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (TPEx: 4174) today announced preclinical data for OBI-992, a potential best-in-class anti-TROP2 Antibody-Drug Conjugate (ADC).

Key Points: 
  • TAIPEI, Taiwan, March 18, 2024 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (TPEx: 4174) today announced preclinical data for OBI-992, a potential best-in-class anti-TROP2 Antibody-Drug Conjugate (ADC).
  • When evaluated against comparative TROP2 ADCs, OBI-992 demonstrated greater antitumor efficacy, superior PK/PD properties, and a favorable safety profile across various preclinical animal models.
  • Additionally, preclinical data will be presented on the novel site-specific proprietary GlycOBI™ ADC platform, demonstrating improved in vivo efficacy and stability in animal model studies.
  • These data will be presented at the American Association of Cancer Research (AACR) Annual Meeting from April 5 to 10, 2024 in San Diego, California (USA).